$ESPR Growth Potential Discussed

Esperion’s potential in the statin-intolerant anti-cholesterol market is discussed. 

“In 2015, the FDA guided that ESPR might have to wait until results of their CVOT in 2022 to file their NDA. This was the first time the FDA had ever provided this type of guidance as previous cholesterol drugs had been approved on LDL-C lowering studies alone.”


read the full discussion in our Daily Pharma Scoop at SeekingAlpha Marketplace.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *